---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-047968"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:23:23.894328+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Relmada shareholders reject equity plan increase and say-on-pay at annual meeting

## Summary
- Director John Glasspool received 7.7M for and 9.98M withheld; Paul Kelly had 11.8M for, 5.88M withheld.
- Ratification of Marcum LLP as auditor approved: 19.98M for, 1.97M against.
- Proposal to increase 2021 Equity Plan by 4.5M shares failed: 4.26M for, 13.41M against.
- Advisory vote on executive compensation did not pass: 7.53M for, 10.12M against.
- 72.9% of outstanding shares (21.99M of 30.17M) were present at the meeting.

## SEC filing metadata
- accession: 0001213900-24-047968
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390024047968/0001213900-24-047968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390024047968/ea0207126-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-047968
- JSON: https://secwatch.observer/filing/0001213900-24-047968.json
- Plain text: https://secwatch.observer/filing/0001213900-24-047968.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.